PATENT CLAIM ANALYSIS

Application Number: 15763366
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "518000"]

Abstract:
Described herein are methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase. Methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a compound that inhibits ATR protein kinase are also described. Exemplary ATR inhibitors are represented by Formulae A-I and A-II or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.

Claim (Index 55):
The method of any one of  claims 36 ,  37 , and  40 - 49 , wherein the compound that inhibits ATR is represented by Formula A-II: or a pharmaceutically salt thereof, wherein: R 10  is independently fluoro, chloro, or \u2014C(J 10 ) 2 CN; J 10  is independently H or C 1-2 alkyl; or two occurrences of J 10 , together with the carbon atom to which they are attached, form a 3-4 membered optionally substituted carbocyclic ring; R 20  is independently H; halo; \u2014CN; NH 2 ; a C 1-2 alkyl optionally substituted with 0-3 occurrences of fluoro; or a C 1-3 aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with \u2014O\u2014, \u2014NR a \u2014, \u2014C(O)\u2014, or \u2014S(O) z ; R 3  is independently H; halo; C 1-4 alkyl optionally substituted with 1-3 occurrences of halo; C 3-4 cycloalkyl; \u2014CN; or a C 1-3 aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with \u2014O\u2014, \u2014NR a \u2014, \u2014C(O)\u2014, or \u2014S(O) z ; R 4  is independently Q 1  or a C 1-10 aliphatic chain wherein up to four methylene units of the aliphatic chain are optionally replaced with \u2014O\u2014, \u2014NR a \u2014, \u2014C(O)\u2014, or \u2014S(O) z \u2014; each R 4  is optionally substituted with 0-5 occurrences of J Q1 ; or R 3  and R 4 , taken together with the atoms to which they are bound, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; the ring formed by R 3  and R 4  is optionally substituted with 0-3 occurrences of J Z ; Q 1  is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring, the 3-7 membered ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; J z  is independently C 1-6 aliphatic, \u2550O, or halo; J Q1  is independently \u2014CN; halo; \u2550O; Q 2 ; or a C 1-8 aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with \u2014O\u2014, \u2014NR a \u2014, \u2014C(O)\u2014, or \u2014S(O) z \u2014; each occurrence of J Q1  is optionally substituted by 0-3 occurrences of J R ; or two occurrences of J Q1  on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J Q1  is optionally substituted with 0-3 occurrences of J X ; or two occurrences of J Q1 , together with Q 1 , form a 6-10 membered saturated or partially unsaturated bridged ring system; Q 2  is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur; J R  is independently \u2014CN; halo; \u2550O; \u2192O; Q 3 ; or a C 1-6 aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with \u2014O\u2014, \u2014NR a \u2014, \u2014C(O)\u2014, or \u2014S(O) z \u2014; each J R  is optionally substituted with 0-3 occurrences of J T ; or two occurrences of J R  on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J R  is optionally substituted with 0-3 occurrences of J X ; or two occurrences of J R , together with Q 2 , form a 6-10 membered saturated or partially unsaturated bridged ring system; Q 3  is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; J X  is independently \u2014CN; \u2550O; halo; or a C 1-4 aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with \u2014O\u2014, \u2014NR a \u2014, \u2014C(O)\u2014, or \u2014S(O) z \u2014; J T  is independently halo, \u2014CN; \u2550O; \u2014OH; a C 1-6 aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with \u2014O\u2014, \u2014NR a \u2014, \u2014C(O)\u2014, or \u2014S(O) z \u2014; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; each occurrence of J T  is optionally substituted with 0-3 occurrences of J M ; or two occurrences of J T  on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J T , together with Q 3 , form a 6-10 membered saturated or partially unsaturated bridged ring system; J M  is independently halo or C 1-6 aliphatic; z is 0, 1 or 2; and R a  is independently H or C 1-4 aliphatic.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 90.0
- Lexical Diversity: 1.71429
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15031426', '15665506', '12988755', '14596052', '15081076']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8082455096750523
- 35 USC 102 Novelty (BERT): 0.5219206853412763
- Combined Prediction Score: 0.7796130272416747
- Mean Citation Score: 311.3153240000001
- Max Citation Score: 332.41208
- Similarity Product: 245.3229402586365

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test